~~<i id='EE706E7AFC'><strike id='EE706E7AFC'><tt id='EE706E7AFC'><pre id='EE706E7AFC'></pre></tt></strike></i>~~

Home» focus» focus

focus

author：knowledge 2025-09-29 23:24:54 Page View：28764

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Lawsuit highlights wrinkle for disputes over surprise medical bills
Next article： Sports medicine is finally prioritizing gender equality

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

The stability of $0 premiums in Medicare Advantage

PabloMartinezMonsivais/APYou’rereadingthewebeditionofHealthCareInc.,STAT’sweeklynewsletterfollowingt

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

CRISPR base editing slashes cholesterol levels in monkeys

Inanewexperiment,CRISPRbaseeditingslashedcholesterollevelsinmonkeysbytargetingtwogenesexpressedinthe